结语 ：诺和诺德此次调转船头，既代表了减肥两巨头同时对三靶点路线的认可，也代表了诺和诺德对自身紧急的自救，同时还是中国资本进行组局撮合的开创象征，相信在未来，中国会有更多优质管线进行出海，被MNC青睐。

如今的全球减肥药市场，诺和诺德与礼来“双雄割据”，两大巨头凭借明星产品，不仅在市场份额上占据绝对优势，还在研发和生产上持续加码，构筑起高高的竞争壁垒，后来者想要突破绝非易事。

Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class, ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...